Here’s a look at four changes in the second round of healthcare bill revisions that just weren’t enough to muster up enough votes.
The Republican Senate’s first attempt to revise its proposed healthcare bill, the Better Care Reconciliation Act (BCRA) of 2017-which would replace the Affordable Care Act (ACA), didn’t have enough support to proceed to a vote. GOP Senators made more revisions and presented them on July 13. But within a few days, four GOP Senators announced that they would not vote for the revised bill, causing it to fail yet again.
Here’s a look at four changes in the second round of revisions that just weren’t enough to muster up enough votes.
Says Hoff, “This is a nod to conservative Republicans because the more affluent are likely the ones who would benefit most as poorer citizens often have little additional income to put into these accounts to begin with, and the pre-tax savings accrues most to those in higher income tax brackets. Many have labeled it as just another tax shelter for wealthy Americans.”
“With the exception of the Cruz Amendment, which would represent a significant change to the status quo and to previous House and Senate proposals, many of the changes in the most recent draft seemed more political than policy-driven,” Fitzgerald concludes. “Senate leadership was seeking votes from previous holdouts, including Senators Cruz and Mike Lee, and also from moderate Senators who were concerned about opiates or the optics of a large tax cut for higher-income taxpayers at the same time Medicaid was cut.”
Karen Appold is a medical writer in Lehigh Valley, Pennsylvania.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More